- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03727867
Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Early Stereotactic Body Radiation Therapy to the Primary Tumor in Advanced Non-small Cell Lung Cancer
A Randomized Ⅲ Phase Trial of Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Early Stereotactic Body Radiation Therapy to the Primary Tumor in Advanced Non-small Cell Lung Cancer Patients Harboring Epidermal Growth Factor Receptor Mutation
Non-small cell lung cancer (NSCLC) is a prevalent disease with high mortality and morbidity, particularly of adenocarcinoma in Asians. Fortunately, with the development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), treatment of lung cancer usher in a new era, resulting in a hit of precise therapy and molecule sequencing. However, it is inevitable for patients to gain acquired resistance of EGFR TKI. Several studies have been demonstrated that there were approximately 30% heterogeneous cells in primary tumors. And emerging studies illuminated that main pattern of treatment failure was the recurrence of primary site. Moreover, it was proved that despite of the drug-resistance cells in progressive site, continual prescription of EGFR TKI in oligometastasis lung cancer could make a difference for patients in progression free survival (PFS) and overall survival (OS), owing to the residual responsive cells in another sites. Therefore, to explore an unique method to control heterogeneous cells in primary site so as to delay or prevent acquired resistance when taking EGFR TKI orally may be of great benefit and therapy.
It is known to all that stereotactic body radiation therapy (SBRT), with the advantage of hypofractionation and rapid release, succeed in several cancers, such as early lung cancer, prostatic, liver cancer and so on, for local control. Numerous reports explained SBRT played an irreplaceable role in progressive NSCLC patients after oral targeted medicine, regardless of EGFR or anaplastic lymphoma kinase (ALK) mutation. And the radiosensitivity of EGFR TKI in vitro and vivo may account for these inspiring results. What's more, it has reported that SBRT could induce inflammatory cell death, activate dendritic cell as well as accelerate antigen presentation in the draining lymph node, leading to antigen-specific adaptive immune response. Nevertheless, although the potential effects of SBRT on advanced NSCLC are obviously, few studies explore the preventive benefits of early SBRT combined with oral EGFR TKI on advanced lung cancer by eliminating the heterogeneous cells in primary site. In addition, the investigators' previous phase II study of SBRT combined with oral EGFR TKI had revealed its safety and potentially improvement of PFS for 6 months.
In this trial, the investigators put sight into assessing the efficacy of early application of SBRT to primary site in the advanced NSCLC patients and provide a hypothesis that early SBRT could strengthen the anti-tumor effect of EGFR TKI through eradicating the heterogenity of initial tumor cells.
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Haihua Yang, MD
- Phone Number: 13819639006
- Email: yhh93181@hotmail.com
Study Contact Backup
- Name: Dongqing Lv, MD
- Phone Number: 13867622009
- Email: lvdq@enzemed.com
Study Locations
-
-
Zhejiang
-
Taizhou, Zhejiang, China, 317000
- Taizhou Hospital, Wenzhou Medical University
-
Contact:
- Haihua Yang, MD
- Phone Number: 13819639006
- Email: yhh93181@hotmail.com
-
Contact:
- Dongqing Lv, MD
- Phone Number: 13867622009
- Email: lvdq@enzemed.com
-
Principal Investigator:
- Hailing Xu, MM
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must sign a study specific informed consent form prior to clinical trial;
- World Healthy Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2 and kamofsky performance status (KPS) >60 at enrollment;
- Patients must have tumors that were proven histopathologically or cytologically as advanced non-small cell lung cancer and that harbored sensitizing EGFR mutation (e.g. exon 19 deletion or exon 21 L858R);
- Estimated life expectancy >8 weeks;
- Patients should have adequate bone marrow function defined as absolute peripheral granulocyte count (AGC) of >/= 1500 cells/mm3, platelet count of >/= 100000 cells/mm3; adequate hepatic function with bilirubin </= 1.5 mg/dl, creatinine clearance >/= 50 ml/min and international normalized ration (INR) 0.8-1.2; adequate lung function: forced expiratory ration in 1 second >80%;
- The number of oligometastasis plus primary lesion should be less that 5, and the maximum diameter of the primary lesion in lung should be under 5 cm, without tracheal and thoracic vessels invasion.
Exclusion Criteria:
- Patients must be withdrawn with prior radiotherapy, chemotherapy, immunotherapy and surgery of chest;
- Uncontrolled intercurrent illness including but not limited to, ongoing or active infection, failure in bone marrow, liver, kidney, heart and lung, or psychiatric illness/social situations that would limit compliance with study requirements;
- Patients who suffered from symptomatic intracranial metastasis or other malignant tumors, such as cervical cancer,skin cancer and so on;
- Patients who participated other clinical drug trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Drug group
Participants were under prescription of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) at the beginning and continued until disease progressed.
|
Oral EGFR TKI begins on day 1 and continues until disease progresses.
Other Names:
|
Experimental: Drug plus SBRT group
After the first month of EGFR TKI orally, participants were given Stereotactic Body Radiation Therapy (SBRT) in dose of 50 Gy/5 F or 60 Gy/8 F for peripheral and central primary tumor, respectively, combined with oral EGFR TKI continually until the primary end point.
|
Oral EGFR TKI begins on day 1 and continues until disease progresses.
Other Names:
Participants were given Stereotactic Body Radiation Therapy in a dose of 60 Gy/8 fraction for the central tumor or 50 Gy/5 fraction for the peripheral lung cancer, respectively.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival
Time Frame: Duration of time from the start of EGFR TKI therapy to the time of disease progression, assessed up to 3 years.
|
Evaluate the effect of EGFR TKI with or without SBRT on progression free survival.
|
Duration of time from the start of EGFR TKI therapy to the time of disease progression, assessed up to 3 years.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Local control rate (LCR)
Time Frame: Up to 3 years.
|
To describe the rate of local control and out-of-field disease progression, irrespectively.
|
Up to 3 years.
|
Overall survival
Time Frame: Duration of time from the start of EGFR TKI therapy to 3 years or until time of death, whichever occurs first.
|
To evaluate overall survival in EGFR TKI therapy with SBRT in comparison to EGFR TKI therapy alone.
|
Duration of time from the start of EGFR TKI therapy to 3 years or until time of death, whichever occurs first.
|
Adverse events
Time Frame: Up to 3 years.
|
The acute and chronic profile associated with the study regimen using CTCAE v5.0.
|
Up to 3 years.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Hailing Xu, MM, Taizhou Hospital, Wenzhou Medical University
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Target-SBRT
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Non-small Cell Lung Cancer
-
Mythic TherapeuticsRecruitingNon-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung CancerUnited States, Australia, Korea, Republic of, United Kingdom
-
AstraZenecaCompletedAdvanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung CancerFrance, Korea, Republic of, United Kingdom, Spain
-
AstraZenecaCompletedAdvanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung CancerBelgium, United States, Korea, Republic of, Taiwan, United Kingdom, Netherlands
-
AstraZenecaCompletedAdvanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung CancerUnited States, France, Germany, Korea, Republic of, Taiwan, United Kingdom, Spain, Italy, Japan, Australia
-
Peking University First HospitalMerck Sharp & Dohme LLCNot yet recruitingAdvanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung CancerChina
-
Gradalis, Inc.WithdrawnLung Neoplasms | Advanced Non-small Cell Lung Cancer | Metastatic Non-small Cell Lung CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyCompletedNon-small Cell Lung Cancer | Advanced Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung CancerUnited States
-
Cancer Research UKBicycle TherapeuticsCompletedNon-Small Cell Lung Cancer | Advanced Solid Tumours | Oesophageal Cancer | Non-Small Cell Lung SarcomaUnited Kingdom
-
Mirati Therapeutics Inc.RecruitingAdvanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung CancerUnited States, Korea, Republic of, Italy, Spain, Czechia, Hungary, Netherlands, Canada, Australia, Austria, Belgium, Germany, Ireland, Israel, Poland, United Kingdom, Taiwan, Portugal
-
LianBio LLCRecruitingAdvanced Solid Tumor | Advanced or Metastatic Non-small Cell Lung CancerChina
Clinical Trials on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
-
M.D. Anderson Cancer CenterUnited States Department of Defense; AstraZenecaTerminated
-
H. Lee Moffitt Cancer Center and Research InstituteArray BioPharmaCompletedNon-Small Cell Lung Cancer | Lung CancerUnited States
-
Calico Life Sciences LLCAbbVieRecruitingAdvanced Solid Tumor CancerUnited States, Korea, Republic of, Israel, Spain, Japan, France
-
Institute of Dermatology, ThailandChumsaeng ChumsaengsriActive, not recruiting
-
ISU Abxis Co., Ltd.Active, not recruitingSolid TumorKorea, Republic of
-
ActelionCompletedHypertension, PulmonaryTaiwan, Korea, Republic of, Belarus, India, Romania, Ukraine
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesUnited States, Croatia, India, Slovakia, Spain, United Kingdom, Finland, Ireland, Germany, Greece, Puerto Rico, Romania, Bulgaria, Latvia, Hong Kong, Lithuania, Portugal
-
Innovent Biologics (Suzhou) Co. Ltd.CompletedType 2 DiabetesChina
-
Eli Lilly and CompanyCompletedDiabetes Mellitus, Type 2Germany, Hungary
-
ActelionActive, not recruitingPulmonary Arterial HypertensionBelgium, Taiwan, Israel, United States, France, China, United Kingdom, Malaysia, Belarus, Canada, Germany, Hungary, Russian Federation, Serbia, Ukraine, Poland